Clinical trials to begin in Vancouver after study finds lactation drug could reduce breast cancer risk

Stock image of a women with cancer. Scientists have discovered that the lactation drug cabergoline could reduce the risk of breast cancer in mothers. Clinical trials are set to get underway. Photo by jgaunion /Getty Images/iStockphoto

Article content

A global study has found that a well-tolerated lactation drug could reduce the risk of breast cancer in mothers, an unexpected discovery that could save the lives of women with a high risk of developing the disease.

Article content

The team, co-led by UBC researchers, found that women who took cabergoline, a medication used to stop milk production after pregnancy loss or when breastfeeding is not possible, were about 70 per cent less likely to develop breast cancer than those who did not take the drug.

Article content

Article content

Article content

Given the significance of the findings, clinical trials will be conducted in Vancouver, Toronto, the U.K. and Spain. Scientists are working on the clinical protocol and hope to test the first patient sometime next year.

Article content

Article content

For the study, published last week in Cancer Discovery, researchers analyzed the health records of more than 150,000 women in Spain and Norway. Those who had the cabergoline treatment had a much a lower incidence of postpartum breast cancer.

Article content

The findings confirmed what scientists already knew about the drug in mice.

Article content

One of the study’s co-authors is Dr. Chris Maxwell, a professor in UBC’s faculty of medicine and investigator at B.C. Children’s Hospital Research Institute. Breast cancer is the leading cause of cancer-related death among younger women, he emphasised, and the majority of these cancers occur during the years after pregnancy.

Article content

“Younger adult females have almost twice as much cancer as younger adult males, and that’s principally due to breast cancer,” he said.

Article content

Researchers tested cabergoline in mice carrying BRCA1 and TP53 mutations, which are associated with aggressive forms of breast cancer.

Article content

Article content

They found that tumour incidence rates fell by about half.

Article content

Article content

Maxwell described the structure of the cells in the mammary gland as being like a fruit tree.

Article content

Similar to how a tree receives energy from the sun and nutrients from the soil for fruit production, the mammary glad receives cues that encourage it to form new branches, in preparation for milk production, he explained.

Article content

“With pregnancy, you get more growth, you get more branching, and then prior to birth, you have what’s called the lactogenic switch, which is basically the tree bears fruit, and these fruit are called the alveolar cells, and they’re the ones that make milk,” he said.

Article content

Then when the mother is done breastfeeding the milk-producing cells regress just like leaves fall off a tree, he said. Cabergoline induces that regression by blocking a hormone called prolactin.

Article content

According to the study, postpartum breast cancer often carries a poor prognosis and urgently requires chemotherapy, particularly for women at elevated risk.

Article content

“The period of transitioning from lactation to post pregnancy is a period that we can intervene,” said Maxwell.